Pippa A. Thomson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pippa A. Thomson has a total of 227 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Mark McIntosh
Royal Infirmary Edinburgh
15 shared publications - David John Porteous
University of Edinburgh
14 shared publications - Mark James Adams
University of Edinburgh
12 shared publications - Caroline Hayward
Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK
10 shared publications - Toni-Kim Clarke
Division of Psychiatry, University of Edinburgh
9 shared publications - Aleix Arnau-Soler
Max Delbrück Center for Molecular Medicine Helmholtz Association Berlin Germany
8 shared publications
Latest Publications
- Open Access
Rare miRNA variants in complex neuropsychiatric pedigrees alter synaptic miRNA gene-targets
Although rare non-coding variants are likely involved in psychiatric disorder susceptibility, their contribution is poorly understood. MicroRNAs (miRNAs) regulate gene expression, and targets in the brain include genes involved in neuronal development and synaptic plasticity. Because single-nucleotide variants (SNVs) can alter miRNA processing and target specificity, this can have disproportionate downstream impact on multiple genes affecting pathways that regulate biological processes, making them compelling candidates for mediating psychiatric disorder risk. We investigated rare miRNA variants in whole-genome sequencing (WGS) data from 25 pedigrees with diagnoses including schizophrenia, psychosis, bipolar disorder, depression, OCD, and substance use disorder. Evidence of segregation with schizophrenia and related psychotic disorders was identified for five rare miRNA variants (two seed-region, one mature-region, and two precursor-region variants), including a SNV in the mature-region of miR-4794, segregating strongly in two unrelated pedigrees and identified in a parent-offspring pair with schizophrenia from a third pedigree. One of these two pedigrees also segregates a seed-region SNV in miR-4423-3p, predicted to significantly impact expression-regulation, causing the loss of synaptic gene-targets associated with psychiatric disorders. Collectively, targets of three of the miRNAs are enriched for schizophrenia rare variant risk genes (p-value: 0.00027): six SCHEMA genes were targeted by miR-96 and four genes by miR-4423-3p. While further understanding of miRNA function and validation is required, this study demonstrates the value of integrating structural modelling, target-shift prediction, and pathway enrichment to interpret non-coding variants. This highlights the utility of WGS for identifying and investigating rare non-coding variation in psychiatric disorder susceptibility, supplementing exome-based approaches.
Open AccessRare miRNA variants in complex neuropsychiatric pedigrees alter synaptic miRNA gene-targets
Although rare non-coding variants are likely involved in psychiatric disorder susceptibility, their contribution is poorly understood. MicroRNAs (miRNAs) regulate gene expression, and targets in the brain include genes involved in neuronal development and synaptic plasticity. Because single-nucleotide variants (SNVs) can alter miRNA processing and target specificity, this can have disproportionate downstream impact on multiple genes affecting pathways that regulate biological processes, making them compelling candidates for mediating psychiatric disorder risk. We investigated rare miRNA variants in whole-genome sequencing (WGS) data from 25 pedigrees with diagnoses including schizophrenia, psychosis, bipolar disorder, depression, OCD, and substance use disorder. Evidence of segregation with schizophrenia and related psychotic disorders was identified for five rare miRNA variants (two seed-region, one mature-region, and two precursor-region variants), including a SNV in the mature-region of miR-4794, segregating strongly in two unrelated pedigrees and identified in a parent-offspring pair with schizophrenia from a third pedigree. One of these two pedigrees also segregates a seed-region SNV in miR-4423-3p, predicted to significantly impact expression-regulation, causing the loss of synaptic gene-targets associated with psychiatric disorders. Collectively, targets of three of the miRNAs are enriched for schizophrenia rare variant risk genes (p-value: 0.00027): six SCHEMA genes were targeted by miR-96 and four genes by miR-4423-3p. While further understanding of miRNA function and validation is required, this study demonstrates the value of integrating structural modelling, target-shift prediction, and pathway enrichment to interpret non-coding variants. This highlights the utility of WGS for identifying and investigating rare non-coding variation in psychiatric disorder susceptibility, supplementing exome-based approaches.
- Open Access
- 21 October 2026
- Published by Oxford University Press (OUP) in Rheumatology
Dysregulation of macrophage colony stimulating factor in Paget’s disease of bone
Objective: To determine if common genetic variants at the chromosome 1p13 locus which predisposes to Paget’s Disease of Bone (PDB) regulate Macrophage Colony stimulating factor (M-CSF) expression in bone cells and to determine if there is dysregulation of M-CSF in patients with PDB. Methods: The regions surrounding single nucleotide polymorphisms (SNP) previously associated with PDB at a genome wide significant level were deleted in clones of MG63 osteoblast-like cells using CRISPR/Cas and levels of M-CSF mRNA and protein were evaluated in cells with and without deletions. Serum M-CSF was measured by ELISA in PDB and controls and values in patients were related to clinical features of PDB and biochemical markers of bone remodelling. Results: Deletion of the region surrounding rs484959 increased expression of M-CSF mRNA by 1.31 fold [95%,1.04-1.58], p = 0.026 and M-CSF protein by 1.91 fold [1.25-2.57], p = 0.013, compared with control cells. Serum M-CSF was significantly elevated in PDB versus controls (mean ± SD = 781.7 ± 678 vs. 541 ± 491 pg/mL, p < 0.001). Furthermore, M-CSF levels were associated with number of affected bones (p = 0.029), bodily pain assessed by SF-36 (p = 0.026) and biochemical markers of bone turnover. Conclusion: The rs484959 SNP is a regulatory variant which modulates M-CSF mRNA and protein expression in osteoblasts. Serum M-CSF is increased in PDB, is associated with pain, disease extent and biochemical markers of bone remodelling. This suggest that there is dysregulation of M-CSF in PDB and that this cytokine may play a role in pathogenesis of the disease.
- 21 October 2026
- Published by Oxford University Press (OUP) in Rheumatology
Open AccessDysregulation of macrophage colony stimulating factor in Paget’s disease of bone
Objective: To determine if common genetic variants at the chromosome 1p13 locus which predisposes to Paget’s Disease of Bone (PDB) regulate Macrophage Colony stimulating factor (M-CSF) expression in bone cells and to determine if there is dysregulation of M-CSF in patients with PDB. Methods: The regions surrounding single nucleotide polymorphisms (SNP) previously associated with PDB at a genome wide significant level were deleted in clones of MG63 osteoblast-like cells using CRISPR/Cas and levels of M-CSF mRNA and protein were evaluated in cells with and without deletions. Serum M-CSF was measured by ELISA in PDB and controls and values in patients were related to clinical features of PDB and biochemical markers of bone remodelling. Results: Deletion of the region surrounding rs484959 increased expression of M-CSF mRNA by 1.31 fold [95%,1.04-1.58], p = 0.026 and M-CSF protein by 1.91 fold [1.25-2.57], p = 0.013, compared with control cells. Serum M-CSF was significantly elevated in PDB versus controls (mean ± SD = 781.7 ± 678 vs. 541 ± 491 pg/mL, p < 0.001). Furthermore, M-CSF levels were associated with number of affected bones (p = 0.029), bodily pain assessed by SF-36 (p = 0.026) and biochemical markers of bone turnover. Conclusion: The rs484959 SNP is a regulatory variant which modulates M-CSF mRNA and protein expression in osteoblasts. Serum M-CSF is increased in PDB, is associated with pain, disease extent and biochemical markers of bone remodelling. This suggest that there is dysregulation of M-CSF in PDB and that this cytokine may play a role in pathogenesis of the disease.
- Open Access
Atypical energy-related symptoms define biologically distinct subtypes of major depressive disorder
Major depressive disorder (MDD) is a complex psychiatric disorder, characterized by a range of mood, cognitive, and neurovegetative symptoms. Current diagnostic criteria treat opposite symptom directions as equivalent; weight gain or loss, and increased or decreased sleep, each count toward a single diagnosis. We defined three subgroups of individuals meeting criteria for MDD: AERS+ (hypersomnia with increased appetite/weight gain), AERS- (insomnia with appetite/weight loss), and an Uncategorized group, and conducted genome-wide association meta-analyses for each (N_eff = 47,858, 156,624, and 215,828, respectively). We identified 27 genome-wide significant loci across subtypes, 4 for AERS+, 10 for AERS- and 13 for Uncategorized. AERS+ showed higher SNP-based heritability (10.9%) and lower polygenicity (1.7% of SNPs) than AERS- (7.9%; 2.9%) or Uncategorized (8.6%; 5.3%), with larger effect sizes at its associated loci. The AERS+ and AERS- subtypes were moderately genetically correlated (r_g= 0.64, se = 0.04). Metabolic traits emerged as a primary differentiator: AERS+ correlated positively with BMI, metabolic syndrome, and related traits, whereas AERS- correlated weakly in the opposite direction. These findings show that the directionality of neurovegetative symptoms indexes genetic heterogeneity within MDD, with metabolic biology as a central axis of differentiation.
Open AccessAtypical energy-related symptoms define biologically distinct subtypes of major depressive disorder
Major depressive disorder (MDD) is a complex psychiatric disorder, characterized by a range of mood, cognitive, and neurovegetative symptoms. Current diagnostic criteria treat opposite symptom directions as equivalent; weight gain or loss, and increased or decreased sleep, each count toward a single diagnosis. We defined three subgroups of individuals meeting criteria for MDD: AERS+ (hypersomnia with increased appetite/weight gain), AERS- (insomnia with appetite/weight loss), and an Uncategorized group, and conducted genome-wide association meta-analyses for each (N_eff = 47,858, 156,624, and 215,828, respectively). We identified 27 genome-wide significant loci across subtypes, 4 for AERS+, 10 for AERS- and 13 for Uncategorized. AERS+ showed higher SNP-based heritability (10.9%) and lower polygenicity (1.7% of SNPs) than AERS- (7.9%; 2.9%) or Uncategorized (8.6%; 5.3%), with larger effect sizes at its associated loci. The AERS+ and AERS- subtypes were moderately genetically correlated (r_g= 0.64, se = 0.04). Metabolic traits emerged as a primary differentiator: AERS+ correlated positively with BMI, metabolic syndrome, and related traits, whereas AERS- correlated weakly in the opposite direction. These findings show that the directionality of neurovegetative symptoms indexes genetic heterogeneity within MDD, with metabolic biology as a central axis of differentiation.
- Open Access
- 21 February 2026
- Published by Elsevier in Biological Psychiatry Global Open Science
- Vol. 6 (3) , 100710
Methylome-Wide Association Studies of Physical Injury Stratified by Depression Status Assesses Exposure by Diagnosis Effects in Oxytocin Signaling and Synaptic Plasticity
- 21 February 2026
- Published by Elsevier in Biological Psychiatry Global Open Science
- Vol. 6 (3) , 100710
Open AccessMethylome-Wide Association Studies of Physical Injury Stratified by Depression Status Assesses Exposure by Diagnosis Effects in Oxytocin Signaling and Synaptic Plasticity
- Open Access
Methylome-wide association studies of traumatic injury identifies differential DNA methylation of synaptic plasticity and GABAergic-signalling
Traumatic physical injury is often associated with psychological trauma and is a risk factor for major depressive disorder (MDD). In Generation Scotland traumatic injury was significantly associated with recurrent major depression (OR = 2.10, 95% CI 1.33-3.33, P LJ=LJ0.0016). and schizotypal symptoms, particularly disorganised thought (βLJ=LJ0.111, 95% CI 0.049-0.177, P LJ=LJ0.0004). We performed methylome-wide analyses of traumatic injury in individuals with MDD and controls separately to investigate the link between traumatic injury and MDD. Nominally significant differences in differential DNA methylation between MDD and control groups were identified at 40 003 CpG sites (p < 0.05). Individuals with recurrent MDD showed significantly higher levels of DNA methylation associated with traumatic injury at CpG sites at the first exon and lower levels at exon boundaries, this was significant different to the association pattern at these sites in controls (mean difference in M-value = 0.0083, P = 21.1×10 -10 , and -0.0125, P = 2.1×10 -174 , respectively). Analyses at the level of CpG site, genes and gene ontologies implicated dysregulation of processes related to synaptic plasticity, including dendrite development, excitatory synapse and GABAergic signalling (normalised enrichment values > 2, FDR q-values < 0.01). Enrichment analyses for regional brain-expression in the recurrent MDD group highlight the limbic lobe and supraoptic nuclei (recurrent MDD FWER = 0.028 and 0.034, respectively). These results suggest that traumatic injury is associated with patterns of DNA methylation differentially in individuals with MDD compared to controls, highlighting the need for novel analysis approaches.
Open AccessMethylome-wide association studies of traumatic injury identifies differential DNA methylation of synaptic plasticity and GABAergic-signalling
Traumatic physical injury is often associated with psychological trauma and is a risk factor for major depressive disorder (MDD). In Generation Scotland traumatic injury was significantly associated with recurrent major depression (OR = 2.10, 95% CI 1.33-3.33, P LJ=LJ0.0016). and schizotypal symptoms, particularly disorganised thought (βLJ=LJ0.111, 95% CI 0.049-0.177, P LJ=LJ0.0004). We performed methylome-wide analyses of traumatic injury in individuals with MDD and controls separately to investigate the link between traumatic injury and MDD. Nominally significant differences in differential DNA methylation between MDD and control groups were identified at 40 003 CpG sites (p < 0.05). Individuals with recurrent MDD showed significantly higher levels of DNA methylation associated with traumatic injury at CpG sites at the first exon and lower levels at exon boundaries, this was significant different to the association pattern at these sites in controls (mean difference in M-value = 0.0083, P = 21.1×10 -10 , and -0.0125, P = 2.1×10 -174 , respectively). Analyses at the level of CpG site, genes and gene ontologies implicated dysregulation of processes related to synaptic plasticity, including dendrite development, excitatory synapse and GABAergic signalling (normalised enrichment values > 2, FDR q-values < 0.01). Enrichment analyses for regional brain-expression in the recurrent MDD group highlight the limbic lobe and supraoptic nuclei (recurrent MDD FWER = 0.028 and 0.034, respectively). These results suggest that traumatic injury is associated with patterns of DNA methylation differentially in individuals with MDD compared to controls, highlighting the need for novel analysis approaches.
- Open Access
Characterisation and Genetic Architecture of Major Depressive Disorder Subgroups Defined by Weight and Sleep Changes
Major depressive disorder, MDD, is highly heterogeneous and thus subgroups with different underlying aetiologies have been postulated. The aim of this work is to further characterise depression subgroups defined using sleep and weight changes. Probable lifetime MDD cases (n = 26,662) from the UK Biobank were stratified into three subgroups defined by self-reported weight and sleep changes during worst episode: (i) increased weight and sleep (↑WS), (ii) decreased weight and sleep (↓WS) and (iii) the remaining uncategorised individuals. Analyses compared the depression characteristics, mental health scores, neurological and inflammatory comorbidities and genetic architecture between subgroups and with 50,147 controls from UK Biobank. In contrast to ↑WS depression, ↓WS depression had a higher age of onset and lower proportion reporting countless or continuous episodes compared to uncategorised individuals. The ↓WS depression also had a higher wellbeing score than the other subgroups. Analyses of subgroup comorbidities identified a novel association between ↑WS depression and epilepsy. Subgroup-specific GWAS identified three genome-wide significant loci associated with ↑WS in genes previously associated with immunometabolic traits and response to anticonvulsants. The effect of BMI adjustment in the genetic analyses of the subgroups and using broader weight-only definitions were also examined. The findings provide further evidence for differences in the characteristics and genetic architecture of depression subgroups defined by sleep and weight change and highlight the importance of dividing non-↑WS individuals into ↓WS and uncategorised subgroups in analyses, as ↓WS symptoms may identify a more acute depression subgroup.
Open AccessCharacterisation and Genetic Architecture of Major Depressive Disorder Subgroups Defined by Weight and Sleep Changes
Major depressive disorder, MDD, is highly heterogeneous and thus subgroups with different underlying aetiologies have been postulated. The aim of this work is to further characterise depression subgroups defined using sleep and weight changes. Probable lifetime MDD cases (n = 26,662) from the UK Biobank were stratified into three subgroups defined by self-reported weight and sleep changes during worst episode: (i) increased weight and sleep (↑WS), (ii) decreased weight and sleep (↓WS) and (iii) the remaining uncategorised individuals. Analyses compared the depression characteristics, mental health scores, neurological and inflammatory comorbidities and genetic architecture between subgroups and with 50,147 controls from UK Biobank. In contrast to ↑WS depression, ↓WS depression had a higher age of onset and lower proportion reporting countless or continuous episodes compared to uncategorised individuals. The ↓WS depression also had a higher wellbeing score than the other subgroups. Analyses of subgroup comorbidities identified a novel association between ↑WS depression and epilepsy. Subgroup-specific GWAS identified three genome-wide significant loci associated with ↑WS in genes previously associated with immunometabolic traits and response to anticonvulsants. The effect of BMI adjustment in the genetic analyses of the subgroups and using broader weight-only definitions were also examined. The findings provide further evidence for differences in the characteristics and genetic architecture of depression subgroups defined by sleep and weight change and highlight the importance of dividing non-↑WS individuals into ↓WS and uncategorised subgroups in analyses, as ↓WS symptoms may identify a more acute depression subgroup.
- 11 May 2022
- Published by Springer Nature in Molecular Psychiatry
- Vol. 27 (9) , 3842-3856
Rare variants implicate NMDA receptor signaling and cerebellar gene networks in risk for bipolar disorder
Bipolar disorder is an often-severe mental health condition characterized by alternation between extreme mood states of mania and depression. Despite strong heritability and the recent identification of 64 common variant risk loci of small effect, pathophysiological mechanisms remain unknown. Here, we analyzed genome sequences from 41 multiply-affected pedigrees and identified variants in 741 genes with nominally significant linkage or association with bipolar disorder. These 741 genes overlapped known risk genes for neurodevelopmental disorders and clustered within gene networks enriched for synaptic and nuclear functions. The top variant in this analysis – prioritized by statistical association, predicted deleteriousness, and network centrality – was a missense variant in the gene encoding D-amino acid oxidase (DAOG131V). Heterologous expression of DAOG131V in human cells resulted in decreased DAO protein abundance and enzymatic activity. In a knock-in mouse model of DAOG131, DaoG130V/+, we similarly found decreased DAO protein abundance in hindbrain regions, as well as enhanced stress susceptibility and blunted behavioral responses to pharmacological inhibition of N-methyl-D-aspartate receptors (NMDARs). RNA sequencing of cerebellar tissue revealed that DaoG130V resulted in decreased expression of two gene networks that are enriched for synaptic functions and for genes expressed, respectively, in Purkinje neurons or granule neurons. These gene networks were also down-regulated in the cerebellum of patients with bipolar disorder compared to healthy controls and were enriched for additional rare variants associated with bipolar disorder risk. These findings implicate dysregulation of NMDAR signaling and of gene expression in cerebellar neurons in bipolar disorder pathophysiology and provide insight into its genetic architecture.
- 11 May 2022
- Published by Springer Nature in Molecular Psychiatry
- Vol. 27 (9) , 3842-3856
Rare variants implicate NMDA receptor signaling and cerebellar gene networks in risk for bipolar disorder
Bipolar disorder is an often-severe mental health condition characterized by alternation between extreme mood states of mania and depression. Despite strong heritability and the recent identification of 64 common variant risk loci of small effect, pathophysiological mechanisms remain unknown. Here, we analyzed genome sequences from 41 multiply-affected pedigrees and identified variants in 741 genes with nominally significant linkage or association with bipolar disorder. These 741 genes overlapped known risk genes for neurodevelopmental disorders and clustered within gene networks enriched for synaptic and nuclear functions. The top variant in this analysis – prioritized by statistical association, predicted deleteriousness, and network centrality – was a missense variant in the gene encoding D-amino acid oxidase (DAOG131V). Heterologous expression of DAOG131V in human cells resulted in decreased DAO protein abundance and enzymatic activity. In a knock-in mouse model of DAOG131, DaoG130V/+, we similarly found decreased DAO protein abundance in hindbrain regions, as well as enhanced stress susceptibility and blunted behavioral responses to pharmacological inhibition of N-methyl-D-aspartate receptors (NMDARs). RNA sequencing of cerebellar tissue revealed that DaoG130V resulted in decreased expression of two gene networks that are enriched for synaptic functions and for genes expressed, respectively, in Purkinje neurons or granule neurons. These gene networks were also down-regulated in the cerebellum of patients with bipolar disorder compared to healthy controls and were enriched for additional rare variants associated with bipolar disorder risk. These findings implicate dysregulation of NMDAR signaling and of gene expression in cerebellar neurons in bipolar disorder pathophysiology and provide insight into its genetic architecture.
- 27 September 2021
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 51, e111-e112
TU32. AN INVESTIGATION OF THE GENETIC ARCHITECTURE OF DEPRESSION SUBGROUPS DEFINED BY WEIGHT AND SLEEP CHANGES
- 27 September 2021
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 51, e111-e112
TU32. AN INVESTIGATION OF THE GENETIC ARCHITECTURE OF DEPRESSION SUBGROUPS DEFINED BY WEIGHT AND SLEEP CHANGES
- Open Access
- 4 February 2019
- Published by Springer Nature in Translational Psychiatry
- Vol. 9 (1) , 1-13
Genome-wide by environment interaction studies of depressive symptoms and psychosocial stress in UK Biobank and Generation Scotland
Stress is associated with poorer physical and mental health. To improve our understanding of this link, we performed genome-wide association studies (GWAS) of depressive symptoms and genome-wide by environment interaction studies (GWEIS) of depressive symptoms and stressful life events (SLE) in two UK population-based cohorts (Generation Scotland and UK Biobank). No SNP was individually significant in either GWAS, but gene-based tests identified six genes associated with depressive symptoms in UK Biobank (DCC, ACSS3, DRD2, STAG1, FOXP2 and KYNU; p < 2.77 × 10−6). Two SNPs with genome-wide significant GxE effects were identified by GWEIS in Generation Scotland: rs12789145 (53-kb downstream PIWIL4; p = 4.95 × 10−9; total SLE) and rs17070072 (intronic to ZCCHC2; p = 1.46 × 10−8; dependent SLE). A third locus upstream CYLC2 (rs12000047 and rs12005200, p < 2.00 × 10−8; dependent SLE) when the joint effect of the SNP main and GxE effects was considered. GWEIS gene-based tests identified: MTNR1B with GxE effect with dependent SLE in Generation Scotland; and PHF2 with the joint effect in UK Biobank (p < 2.77 × 10−6). Polygenic risk scores (PRSs) analyses incorporating GxE effects improved the prediction of depressive symptom scores, when using weights derived from either the UK Biobank GWAS of depressive symptoms (p = 0.01) or the PGC GWAS of major depressive disorder (p = 5.91 × 10−3). Using an independent sample, PRS derived using GWEIS GxE effects provided evidence of shared aetiologies between depressive symptoms and schizotypal personality, heart disease and COPD. Further such studies are required and may result in improved treatments for depression and other stress-related conditions.
- 4 February 2019
- Published by Springer Nature in Translational Psychiatry
- Vol. 9 (1) , 1-13
Open AccessGenome-wide by environment interaction studies of depressive symptoms and psychosocial stress in UK Biobank and Generation Scotland
Stress is associated with poorer physical and mental health. To improve our understanding of this link, we performed genome-wide association studies (GWAS) of depressive symptoms and genome-wide by environment interaction studies (GWEIS) of depressive symptoms and stressful life events (SLE) in two UK population-based cohorts (Generation Scotland and UK Biobank). No SNP was individually significant in either GWAS, but gene-based tests identified six genes associated with depressive symptoms in UK Biobank (DCC, ACSS3, DRD2, STAG1, FOXP2 and KYNU; p < 2.77 × 10−6). Two SNPs with genome-wide significant GxE effects were identified by GWEIS in Generation Scotland: rs12789145 (53-kb downstream PIWIL4; p = 4.95 × 10−9; total SLE) and rs17070072 (intronic to ZCCHC2; p = 1.46 × 10−8; dependent SLE). A third locus upstream CYLC2 (rs12000047 and rs12005200, p < 2.00 × 10−8; dependent SLE) when the joint effect of the SNP main and GxE effects was considered. GWEIS gene-based tests identified: MTNR1B with GxE effect with dependent SLE in Generation Scotland; and PHF2 with the joint effect in UK Biobank (p < 2.77 × 10−6). Polygenic risk scores (PRSs) analyses incorporating GxE effects improved the prediction of depressive symptom scores, when using weights derived from either the UK Biobank GWAS of depressive symptoms (p = 0.01) or the PGC GWAS of major depressive disorder (p = 5.91 × 10−3). Using an independent sample, PRS derived using GWEIS GxE effects provided evidence of shared aetiologies between depressive symptoms and schizotypal personality, heart disease and COPD. Further such studies are required and may result in improved treatments for depression and other stress-related conditions.
- Open Access
- 31 January 2019
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 20 (2) , 329-341
Genome-wide association study of antidepressant treatment resistance in a population-based cohort using health service prescription data and meta-analysis with GENDEP
Antidepressants demonstrate modest response rates in the treatment of major depressive disorder (MDD). Despite previous genome-wide association studies (GWAS) of antidepressant treatment response, the underlying genetic factors are unknown. Using prescription data in a population and family-based cohort (Generation Scotland: Scottish Family Health Study; GS:SFHS), we sought to define a measure of (a) antidepressant treatment resistance and (b) stages of antidepressant resistance by inferring antidepressant switching as non-response to treatment. GWAS were conducted separately for antidepressant treatment resistance in GS:SFHS and the Genome-based Therapeutic Drugs for Depression (GENDEP) study and then meta-analysed (meta-analysis n = 4213, cases = 358). For stages of antidepressant resistance, a GWAS on GS:SFHS only was performed (n = 3452). Additionally, we conducted gene-set enrichment, polygenic risk scoring (PRS) and genetic correlation analysis. We did not identify any significant loci, genes or gene sets associated with antidepressant treatment resistance or stages of resistance. Significant positive genetic correlations of antidepressant treatment resistance and stages of resistance with neuroticism, psychological distress, schizotypy and mood disorder traits were identified. These findings suggest that larger sample sizes are needed to identify the genetic architecture of antidepressant treatment response, and that population-based observational studies may provide a tractable approach to achieving the necessary statistical power.
- 31 January 2019
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 20 (2) , 329-341
Open AccessGenome-wide association study of antidepressant treatment resistance in a population-based cohort using health service prescription data and meta-analysis with GENDEP
Antidepressants demonstrate modest response rates in the treatment of major depressive disorder (MDD). Despite previous genome-wide association studies (GWAS) of antidepressant treatment response, the underlying genetic factors are unknown. Using prescription data in a population and family-based cohort (Generation Scotland: Scottish Family Health Study; GS:SFHS), we sought to define a measure of (a) antidepressant treatment resistance and (b) stages of antidepressant resistance by inferring antidepressant switching as non-response to treatment. GWAS were conducted separately for antidepressant treatment resistance in GS:SFHS and the Genome-based Therapeutic Drugs for Depression (GENDEP) study and then meta-analysed (meta-analysis n = 4213, cases = 358). For stages of antidepressant resistance, a GWAS on GS:SFHS only was performed (n = 3452). Additionally, we conducted gene-set enrichment, polygenic risk scoring (PRS) and genetic correlation analysis. We did not identify any significant loci, genes or gene sets associated with antidepressant treatment resistance or stages of resistance. Significant positive genetic correlations of antidepressant treatment resistance and stages of resistance with neuroticism, psychological distress, schizotypy and mood disorder traits were identified. These findings suggest that larger sample sizes are needed to identify the genetic architecture of antidepressant treatment response, and that population-based observational studies may provide a tractable approach to achieving the necessary statistical power.